Margaret P Adam

Summary

Affiliation: University of Washington
Country: USA

Publications

  1. doi request reprint The all-or-none phenomenon revisited
    Margaret P Adam
    Division of Genetic Medicine, Department of Pediatrics, University of Washington School of Medicine and Seattle Children s Hospital, Seattle, Washington 98105 0371, USA
    Birth Defects Res A Clin Mol Teratol 94:664-9. 2012
  2. doi request reprint Ambiguous genitalia: what prenatal genetic testing is practical?
    Margaret P Adam
    Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington, USA
    Am J Med Genet A 158:1337-43. 2012
  3. doi request reprint Evolving knowledge of the teratogenicity of medications in human pregnancy
    Margaret P Adam
    University of Washington in Seattle, and Seattle Children s Hospital, 4800 Sand Point Way NE, Seattle, WA 98105 0371, USA
    Am J Med Genet C Semin Med Genet 157:175-82. 2011

Detail Information

Publications3

  1. doi request reprint The all-or-none phenomenon revisited
    Margaret P Adam
    Division of Genetic Medicine, Department of Pediatrics, University of Washington School of Medicine and Seattle Children s Hospital, Seattle, Washington 98105 0371, USA
    Birth Defects Res A Clin Mol Teratol 94:664-9. 2012
    ....
  2. doi request reprint Ambiguous genitalia: what prenatal genetic testing is practical?
    Margaret P Adam
    Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington, USA
    Am J Med Genet A 158:1337-43. 2012
    ..However, targeted molecular testing for rare DSD conditions in the absence of a family history of DSD has a low yield...
  3. doi request reprint Evolving knowledge of the teratogenicity of medications in human pregnancy
    Margaret P Adam
    University of Washington in Seattle, and Seattle Children s Hospital, 4800 Sand Point Way NE, Seattle, WA 98105 0371, USA
    Am J Med Genet C Semin Med Genet 157:175-82. 2011
    ..The lack of information needed to assess the safety of drug treatments during human pregnancy remains a serious public health problem. A more active approach to post-marketing surveillance for teratogenic effects is necessary...